All In Biotech

Drug Trial Radar · NCT02970292

Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia (ENHANCE-1)

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia

Last checked: Nov 20, 2026Latest source record: Jun 17, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 396 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

396

Actual

Start

Oct 26, 2016

Primary completion

May 28, 2019

Study completion Jun 25, 2019

Sponsor

Lead sponsor
ACADIA Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Nov 22, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the efficacy and safety of adjunctive pimavanserin compared with adjunctive placebo in the treatment of schizophrenia

Conditions

  • Schizophrenia

Interventions

  • PimavanserinDrug

    Pimavanserin 34 mg, 20 mg, or 10 mg , taken as two tablets once daily by mouth

  • PlaceboDrug

    Placebo, taken as two tablets, once daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to Week 6 in the Positive and Negative Syndrome Scale (PANSS) Total ScoreTime frame: From baseline to Week 6

Locations

105 sites in 10 countries. Site status is shown where the registry gives one.

  • Site not named

    Phoenix, Arizona

  • Site not named

    Little Rock, Arkansas

  • Site not named

    Rogers, Arkansas

  • Site not named

    Bellflower, California

  • Site not named

    Cerritos, California

  • Site not named

    Culver City, California

  • Site not named

    Lemon Grove, California

  • Site not named

    Long Beach, California

  • Site not named

    San Diego, California

  • Site not named

    San Diego, California

  • Site not named

    Santa Ana, California

  • Site not named

    Torrance, California

  • Site not named

    Boca Raton, Florida

  • Site not named

    Lauderhill, Florida

  • Site not named

    Miami, Florida

  • Site not named

    Atlanta, Georgia

  • Site not named

    Atlanta, Georgia

  • Site not named

    Chicago, Illinois

  • Site not named

    Chicago, Illinois

  • Site not named

    Hoffman Estates, Illinois

  • Site not named

    Lake Charles, Louisiana

  • Site not named

    Catonsville, Maryland

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Las Vegas, Nevada

  • Site not named

    Berlin, New Jersey

  • Site not named

    Cedarhurst, New York

  • Site not named

    Jamaica, New York

  • Site not named

    Rochester, New York

  • Site not named

    Charlotte, North Carolina

  • Site not named

    Dayton, Ohio

  • Site not named

    Charleston, South Carolina

  • Site not named

    Richardson, Texas

  • Site not named

    Salt Lake City, Utah

  • Site not named

    Burgas, Bulgaria

  • Site not named

    Pazardzhik, Bulgaria

  • Site not named

    Plovdiv, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

  • Site not named

    Sofia, Bulgaria

Showing 40 of 105 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.